by Team PCM | May 12, 2021 | Blog Post, Pharmacy Benefits
It has been 15 years since the widespread adoption of biosimilar medications in the European Union. Ten years later, in March 2015, the first biosimilar was approved by the FDA for use in the United States. Unlike the EU, biosimilars have struggled to take hold in...
by Team PCM | Apr 15, 2021 | Blog Post, Data Analytics, Pharmacy Benefits
Medication adherence is a longstanding issue within the complex American healthcare system. Made worse by the global pandemic, nonadherence to prescribed medications is the result of many factors with far-reaching impacts on patients and health plans. Two obstacles...
by Team PCM | Feb 17, 2021 | Blog Post, Pharmacy Benefits
Clinically driven models are creating a buzz across healthcare. A clinically-driven model moves from a volume-based revenue system to a strategy focused on the amount saved by improving health in the pharmacy space. This strategy includes considering medication...
by Team PCM | Nov 17, 2020 | Blog Post, Pharmacy Benefits
There are six significant stakeholders in the complex drug distribution system: pharmaceutical manufacturer, plan sponsor, pharmacy, PBM, wholesaler, and patient. Whether paying for prescriptions or determining the price of medications, each stakeholder plays an...
by Team PCM | Oct 9, 2020 | Blog Post, Pharmacy Benefits
The cost of prescription medications is rising, but one sub-set of drugs may be disproportionately eating away at financial resources. Specialty drugs cost an average of $79,000 per year. What are specialty drugs, and what (or who) controls their high price tags? What...
by Team PCM | Jan 14, 2020 | Blog Post, Pharmacy Benefits
Along with fireworks, champagne, and resolutions, we rang in 2020 with price increases on hundreds of drugs. New year, same challenge. However, even amid increasing prices, you can build a comprehensive cost containment strategy. Foundational to developing meaningful...
